ZYME
HEALTHCAREZymeworks BC Inc
$27.61+0.93 (+3.49%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving ZYME Today?
No stock-specific AI insight has been generated for ZYME yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$10.93$29.75
$27.61
Fundamentals
Market Cap$2.1B
P/E Ratio—
EPS$-1.08
Dividend Yield—
Dividend / Share—
ROE-0.3%
Profit Margin-0.8%
Debt / Equity—
Trading
Volume427K
Avg Volume (10D)—
Shares Outstanding73.8M
ZYME News
20 articles- Zymeworks Inc. (ZYME) Reports Q1 Loss, Misses Revenue EstimatesYahoo Finance·May 7, 2026
- Zymeworks Provides Corporate Update and Reports First Quarter 2026 Financial ResultsYahoo Finance·May 7, 2026
- Royalty Pharma Q1 Earnings Call HighlightsMarketbeat·May 6, 2026
- uniQure (QURE) Reports Q1 Loss, Misses Revenue EstimatesYahoo Finance·May 5, 2026
- Vertex Pharmaceuticals (VRTX) Q1 Earnings and Revenues Beat EstimatesYahoo Finance·May 4, 2026
- April 2026's Top 3 Stocks That May Be Trading Below Estimated Fair ValueYahoo Finance·Apr 27, 2026
- Zymeworks Highlights Royalty-Fueled Pivot at Bloom Burton, Eyes Multibillion-Dollar ZiiheraMarketbeat·Apr 26, 2026
- Capricorn Fund Managers Dumps $18.4 Million Worth of Waystar Stock in Q1Motley Fool·Apr 24, 2026
- Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026Yahoo Finance·Apr 21, 2026
- Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting PlatformGlobeNewswire Inc.·Apr 17, 2026
- How Investors May Respond To Zymeworks (ZYME) Hiring EcoR1 Executives To Lead R&D And DealsYahoo Finance·Apr 17, 2026
- Jazz Pharmaceuticals Touts Record $4.3B 2025 Revenue, Reaffirms 2026 Outlook at ConferenceMarketbeat·Apr 16, 2026
- Zymeworks to Report First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026Yahoo Finance·Apr 16, 2026
- Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of GrowthGlobeNewswire Inc.·Apr 9, 2026
- Exchange-Traded Funds, Equity Futures Gain Pre-Bell Wednesday as Iran War De-Escalation Hopes Drive SentimentYahoo Finance·Apr 1, 2026
- Zymeworks Appoints Kristin Stafford as Chief Financial OfficerGlobeNewswire Inc.·Apr 1, 2026
- How Investors May Respond To Zymeworks (ZYME) Fast Track Nod For Ovarian Cancer ADC ZW191Yahoo Finance·Mar 31, 2026
- Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug ConjugateGlobeNewswire Inc.·Mar 30, 2026
- Zymeworks Announces Participation in Upcoming Investor ConferencesYahoo Finance·Mar 24, 2026
- Zymeworks Announces Presentations for Ziihera® (zanidatamab-hrii) at 2026 AACR Annual MeetingYahoo Finance·Mar 18, 2026
All 20 articles loaded
Price Data
Open$26.97
Previous Close$26.68
Day High$27.64
Day Low$26.60
52 Week High$29.75
52 Week Low$10.93
52-Week Range
$10.93$29.75
$27.61
Fundamentals
Market Cap$2.1B
P/E Ratio—
EPS$-1.08
Dividend Yield—
Dividend / Share—
ROE-0.3%
Profit Margin-0.8%
Debt / Equity—
Trading
Volume427K
Avg Volume (10D)—
Shares Outstanding73.8M
About Zymeworks BC Inc
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops and markets biotherapeutic products for the treatment of cancer. The company is headquartered in Vancouver, Canada.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—